{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:07:44Z","timestamp":1785892064645,"version":"3.56.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T00:00:00Z","timestamp":1475107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/nrcardio.2016.151","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T11:26:07Z","timestamp":1475148367000},"page":"719-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Bioresorbable vascular scaffolds \u2014 basic concepts and clinical outcome"],"prefix":"10.1038","volume":"13","author":[{"given":"Ciro","family":"Indolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,29]]},"reference":[{"key":"BFnrcardio2016151_CR1","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.amjcard.2005.01.040","volume":"95","author":"C Indolfi","year":"2005","unstructured":"Indolfi, C., Pavia, M. & Angelillo, I. F. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am. J. Cardiol. 95, 1146\u20131152 (2005).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio2016151_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2007.04.032","volume":"50","author":"DR Holmes","year":"2007","unstructured":"Holmes, D. R. et al. Thrombosis and drug-eluting stents: an objective appraisal. J. Am. Coll. Cardiol. 50, 109\u2013118 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016151_CR3","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1161\/CIRCRESAHA.115.308237","volume":"118","author":"C Gareri","year":"2016","unstructured":"Gareri, C., De Rosa, S. & Indolfi, C. MicroRNAs for restenosis and thrombosis after vascular injury. Circ. Res. 118, 1170\u20131184 (2016).","journal-title":"Circ. Res."},{"key":"BFnrcardio2016151_CR4","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1093\/eurheartj\/ehv203","volume":"36","author":"RA Byrne","year":"2015","unstructured":"Byrne, R. A. et al. Report of a European Society of Cardiology\u2013European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur. Heart J. 36, 2608\u20132620 (2015).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2016151_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/CIRCINTERVENTIONS.109.859173","volume":"2","author":"JA Ormiston","year":"2009","unstructured":"Ormiston, J. A. & Serruys, P. W. Bioabsorbable coronary stents. Circ. Cardiovasc. Interv. 2, 255\u2013260 (2009).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR6","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.4244\/EIJV9I11A217","volume":"9","author":"PW Serruys","year":"2014","unstructured":"Serruys, P. W. et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 9, 1271\u20131284 (2014).","journal-title":"EuroIntervention"},{"key":"BFnrcardio2016151_CR7","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1161\/CIRCULATIONAHA.110.970772","volume":"122","author":"PW Serruys","year":"2010","unstructured":"Serruys, P. W. et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 122, 2301\u20132312 (2010).","journal-title":"Circulation"},{"key":"BFnrcardio2016151_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.4244\/EIJV10I6A118","volume":"10","author":"YJ Zhang","year":"2014","unstructured":"Zhang, Y. J. et al. Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. EuroIntervention. 10, 672\u2013680 (2014).","journal-title":"EuroIntervention."},{"key":"BFnrcardio2016151_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ccd.21136","volume":"70","author":"S Tanimoto","year":"2007","unstructured":"Tanimoto, S. et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimuseluting cobalt chromiumcoronary stent: insights fromthe ABSORB and SPIRIT trials. Catheter Cardiovasc. Interv. 70, 515\u2013523 (2007).","journal-title":"Catheter Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR10","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jcin.2010.07.016","volume":"3","author":"J Gomez-Lara","year":"2010","unstructured":"Gomez-Lara, J. et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc. Interv. 3, 1190\u20131198 (2010).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.actbio.2015.08.009","volume":"26","author":"J Ferdous","year":"2015","unstructured":"Ferdous, J., Kolachalama, V. B., Kolandaivelu, K. & Shazly, T. Degree of bioresorbable vascular scaffold expansion modulates loss of essential function. Acta Biomater. 26, 195\u2013204 (2015).","journal-title":"Acta Biomater."},{"key":"BFnrcardio2016151_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1161\/CIRCIMAGING.114.001727","volume":"7","author":"C Indolfi","year":"2014","unstructured":"Indolfi, C. et al. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation. Circ. Cardiovasc. Imaging 7, 755\u2013757 (2014).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"BFnrcardio2016151_CR13","doi-asserted-by":"publisher","unstructured":"Ishida, K., Giacchi, G., Brugaletta, S., Garc\u0131a-Alvarez, A. & Sabate, M. Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis? Cardiovasc. Revasc. Med. http:\/\/dx.doi.org\/10.1016\/j.carrev.2016.05.013 (2016).","DOI":"10.1016\/j.carrev.2016.05.013"},{"key":"BFnrcardio2016151_CR14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0140-6736(09)60325-1","volume":"373","author":"PW Serruys","year":"2009","unstructured":"Serruys, P. W. et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373, 897\u2013910 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio2016151_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10554-010-9769-y","volume":"28","author":"G Sarno","year":"2012","unstructured":"Sarno, G. et al. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. Int. J. Cardiovasc. Imaging 28, 51\u201358 (2012).","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"BFnrcardio2016151_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCINTERVENTIONS.112.971549","volume":"5","author":"JA Ormiston","year":"2012","unstructured":"Ormiston, J. A. et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ. Cardiovasc. Interv. 5, 620\u2013632 (2012).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR17","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.jacc.2011.05.050","volume":"58","author":"PW Serruys","year":"2011","unstructured":"Serruys, P. W. et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis 12-month clinical and imaging outcomes. J. Am. Coll. Cardiol. 58, 1578\u20131588 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016151_CR18","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/eurheartj\/ehr466","volume":"33","author":"S Brugaletta","year":"2012","unstructured":"Brugaletta, S. et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur. Heart J. 33, 1325\u20131333 (2012).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2016151_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jacc.2005.01.062","volume":"46","author":"M Togni","year":"2005","unstructured":"Togni, M. et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46, 231\u2013236 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016151_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/eurheartj\/ehi571","volume":"27","author":"SH Hofma","year":"2006","unstructured":"Hofma, S. H. et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J. 27, 166\u2013170 (2006).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2016151_CR21","first-page":"996","volume":"11","author":"C Simsek","year":"2016","unstructured":"Simsek, C. et al. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities. EuroIntervention 11, 996\u20131003 (2016).","journal-title":"EuroIntervention"},{"key":"BFnrcardio2016151_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)00447-X","volume":"387","author":"M Haude","year":"2016","unstructured":"Haude, M. et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions(BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomized, first-in-man trial. Lancet 387, 31\u201339 (2016).","journal-title":"Lancet"},{"key":"BFnrcardio2016151_CR23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2015.12.019","volume":"67","author":"S Puricel","year":"2016","unstructured":"Puricel, S. et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J. Am. Coll. Cardiol. 67, 921\u2013931 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016151_CR24","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1002\/ccd.25569","volume":"85","author":"C Costopoulos","year":"2015","unstructured":"Costopoulos, C. et al. Comparison of early clinical outcomes between Absorb bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc. Interv. 85, E10\u2013E15 (2015).","journal-title":"Catheter Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jcin.2014.01.165","volume":"7","author":"A Mattesini","year":"2014","unstructured":"Mattesini, A. et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc. Interv. 7, 741\u2013750 (2014).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR26","first-page":"316","volume":"28","author":"D Robaei","year":"2016","unstructured":"Robaei, D., Back, L., Ooi, S. Y., Pitney, M. & Jepson, N. Twelve-month outcomes with bioresorbable everolimus-eluting scaffold: results of the ESHC-BVS Registry at two Australian centers. J. Invasive Cardiol. 28, 316\u2013322 (2016).","journal-title":"J. Invasive Cardiol."},{"key":"BFnrcardio2016151_CR27","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.jcin.2015.07.026","volume":"8","author":"Y Ishibashi","year":"2015","unstructured":"Ishibashi, Y. et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). JACC Cardiovasc. Interv. 8, 1715\u20131726 (2015).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR28","doi-asserted-by":"publisher","first-page":"e1580","DOI":"10.4244\/EIJV11I14A308","volume":"11","author":"T Miyazaki","year":"2016","unstructured":"Miyazaki, T. et al. The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: a comparison with conventional balloon predilatation. EuroIntervention 11, e1580\u2013e1588 (2016).","journal-title":"EuroIntervention"},{"key":"BFnrcardio2016151_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1161\/01.CIR.101.6.689","volume":"101","author":"G Heusch","year":"2000","unstructured":"Heusch, G. et al. \u03b1-Adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 101, 689\u2013694 (2000).","journal-title":"Circulation"},{"key":"BFnrcardio2016151_CR30","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/01.CIR.86.4.1116","volume":"86","author":"C Indolfi","year":"1992","unstructured":"Indolfi, C. et al. Role of alpha 2-adrenoceptors in normal and atherosclerotic human coronary circulation. Circulation 86, 1116\u20131124 (1992).","journal-title":"Circulation"},{"key":"BFnrcardio2016151_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jcin.2015.11.019","volume":"9","author":"H Kawamoto","year":"2016","unstructured":"Kawamoto, H., Jabbour, R. J., Tanaka, A., Latib, A. & Colombo, A. The bioresorbable scaffold: will oversizing affect outcomes? JACC Cardiovasc. Interv. 9, 299\u2013300 (2016).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jcin.2015.09.021","volume":"9","author":"A Colombo","year":"2016","unstructured":"Colombo, A. & Ruparelia, N. Who is thrombogenic: the scaffold or the doctor? Back to the future! JACC Cardiovasc. Interv. 9, 25\u201327 (2016).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR33","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/eurheartj\/ehv711","volume":"37","author":"G Souteyrand","year":"2016","unstructured":"Souteyrand, G. et al. Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. Eur. Heart J. 37, 1208\u20131216 (2016).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2016151_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12872-015-0163-5","volume":"15","author":"S Sorrentino","year":"2015","unstructured":"Sorrentino, S. et al. The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment. BMC Cardiovasc. Disord. 15, 169 (2015).","journal-title":"BMC Cardiovasc. Disord."},{"key":"BFnrcardio2016151_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijcard.2016.01.202","volume":"208","author":"S Biscaglia","year":"2016","unstructured":"Biscaglia, S. et al. Bioresorbable scaffold versus second generation drug eluting stent in long coronary lesions requiring overlap: a propensity-matched comparison (the UNDERDOGS study). Int. J. Cardiol. 208, 40\u201345 (2016).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio2016151_CR36","first-page":"E34","volume":"28","author":"H Kawamoto","year":"2016","unstructured":"Kawamoto, H., Ruparelia, N., Tanaka, A., Latib, A. & Colombo, A. Minimal acute recoil following bioresorbable scaffold implantation in fibrocalcific lesion detected by optical frequency-domain imaging. J. Invasive Cardiol. 28, E34\u2013E36 (2016).","journal-title":"J. Invasive Cardiol."},{"key":"BFnrcardio2016151_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ijcard.2016.07.033","volume":"221","author":"G Caiazzo","year":"2016","unstructured":"Caiazzo, G. et al. Optical coherence tomography guidance for percutaneous coronary intervention with bioresorbable scaffolds. Int. J. Cardiol. 221, 352\u2013358 (2016).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio2016151_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/01.CIR.102.4.399","volume":"102","author":"H Tamai","year":"2000","unstructured":"Tamai, H. et al. Initial 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102, 399\u2013404 (2000).","journal-title":"Circulation"},{"key":"BFnrcardio2016151_CR39","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1161\/CIRCULATIONAHA.110.000901","volume":"125","author":"S Nishio","year":"2012","unstructured":"Nishio, S. et al. Long-term (>10 years) clinical outcomes of first-in-humans biodegradable poly-l-lactic acid coronary stents Igaki-Tamai stents. Circulation 125, 2343\u20132352 (2012).","journal-title":"Circulation"},{"key":"BFnrcardio2016151_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0140-6736(14)61455-0","volume":"385","author":"PW Serruys","year":"2012","unstructured":"Serruys, P. W. et al. Bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385, 43\u201354 (2012).","journal-title":"Lancet"},{"key":"BFnrcardio2016151_CR41","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jacc.2015.09.054","volume":"66","author":"R Gao","year":"2015","unstructured":"Gao, R. et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J. Am. Coll. Cardiol. 66, 2298\u20132309 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016151_CR42","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","volume":"373","author":"SG Ellis","year":"2015","unstructured":"Ellis, S. G. et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N. Engl. J. Med. 373, 1905\u20131915 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio2016151_CR43","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/eurheartj\/ehv435","volume":"36","author":"T Kimura","year":"2015","unstructured":"Kimura, T. et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds versus everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur. Heart J. 36, 3332\u20133342 (2015).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2016151_CR44","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jacc.2014.12.017","volume":"65","author":"S Puricel","year":"2015","unstructured":"Puricel, S. et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J. Am. Coll. Cardiol. 65, 791\u2013801 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016151_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/eurheartj\/ehv500","volume":"37","author":"M Sabat\u00e9","year":"2016","unstructured":"Sabat\u00e9, M. Everolimus-eluting bioresorbable stent versus durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur. Heart J. 37, 229\u2013240 (2016).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2016151_CR46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijcard.2015.07.101","volume":"201","author":"G Caiazzo","year":"2015","unstructured":"Caiazzo, G. et al. Absorb bioresorbable vascular scaffold: what have we learned after 5 years of clinical experience? Int. J. Cardiol. 201, 129\u2013136 (2015).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio2016151_CR47","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.4244\/EIJY14M07_11","volume":"10","author":"D Capodanno","year":"2015","unstructured":"Capodanno, D. et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 10, 1144\u20131153 (2015).","journal-title":"EuroIntervention"},{"key":"BFnrcardio2016151_CR48","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.4244\/EIJY14M08_08","volume":"10","author":"RP Kraak","year":"2015","unstructured":"Kraak, R. P. et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI registry. EuroIntervention 10, 1160\u20131168 (2015).","journal-title":"EuroIntervention"},{"key":"BFnrcardio2016151_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4244\/EIJY14M12_10","volume":"11","author":"J W\u00f6hrle","year":"2015","unstructured":"W\u00f6hrle, J. et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 11, 149\u2013156 (2015).","journal-title":"EuroIntervention"},{"key":"BFnrcardio2016151_CR50","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/ccd.26346","volume":"87","author":"P Hoppmann","year":"2016","unstructured":"Hoppmann, P. et al. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry. Catheter Cardiovasc. Interv. 87, 822\u2013829 (2016).","journal-title":"Catheter Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR51","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.4244\/EIJV10I12A243","volume":"10","author":"A Abizaid","year":"2015","unstructured":"Abizaid, A. et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 10, 1396\u20131401 (2015).","journal-title":"EuroIntervention"},{"key":"BFnrcardio2016151_CR52","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.5603\/KP.a2014.0147","volume":"72","author":"\u0141 Rzeszutko","year":"2014","unstructured":"Rzeszutko, \u0141. et al. Contemporary use of bioresorbable vascular scaffolds (BVS) in patients with stable angina and acute coronary syndromes. Polish National Registry. Kardiol. Pol. 72, 1394\u20131399 (2014).","journal-title":"Kardiol. Pol."},{"key":"BFnrcardio2016151_CR53","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.jcin.2016.04.035","volume":"9","author":"CM Felix","year":"2016","unstructured":"Felix, C. M. et al. Mid- to long-term clinical outcomes of patients treated with the everolimus-eluting bioresorbable vascular scaffold: The BVS Expand Registry. JACC Cardiovasc. Interv. 9, 1652\u20131663 (2016).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.20452\/pamw.2550","volume":"124","author":"D Dudek","year":"2014","unstructured":"Dudek, D. et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study. Pol. Arch. Med. Wewn. 124, 669\u2013677 (2014).","journal-title":"Pol. Arch. Med. Wewn."},{"key":"BFnrcardio2016151_CR55","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.4244\/EIJV9I9A176","volume":"9","author":"T Gori","year":"2014","unstructured":"Gori, T. et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 9, 1036\u20131041 (2014).","journal-title":"EuroIntervention"},{"key":"BFnrcardio2016151_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00392-013-0630-x","volume":"103","author":"J Wiebe","year":"2014","unstructured":"Wiebe, J. et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin. Res. Cardiol. 103, 141\u2013148 (2014).","journal-title":"Clin. Res. Cardiol."},{"key":"BFnrcardio2016151_CR57","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4244\/EIJV9I4A80","volume":"9","author":"T Kajiya","year":"2013","unstructured":"Kajiya, T. et al. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention 9, 501\u2013504 (2013).","journal-title":"EuroIntervention"},{"key":"BFnrcardio2016151_CR58","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/eurheartj\/eht545","volume":"35","author":"V Koc\u02d8ka","year":"2014","unstructured":"Koc\u02d8ka, V. et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. Eur. Heart J. 35, 787\u2013794 (2014).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2016151_CR59","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/eurheartj\/eht546","volume":"35","author":"R Diletti","year":"2014","unstructured":"Diletti, R. et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur. Heart J. 35, 777\u2013786 (2014).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2016151_CR60","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.amjcard.2015.05.049","volume":"116","author":"B Cortese","year":"2015","unstructured":"Cortese, B. et al. Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions. Am. J. Cardiol. 116, 705\u2013710 (2015).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio2016151_CR61","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcin.2014.10.005","volume":"8","author":"S Brugaletta","year":"2015","unstructured":"Brugaletta, S. et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc. Interv. 8, 189\u2013197 (2015).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR62","first-page":"461","volume":"27","author":"O Goktekin","year":"2015","unstructured":"Goktekin, O. et al. Evaluation of the safety of everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with chronic total coronary occlusions: acute procedural and short-term clinical results. J. Invasive Cardiol. 27, 461\u2013466 (2015).","journal-title":"J. Invasive Cardiol."},{"key":"BFnrcardio2016151_CR63","doi-asserted-by":"publisher","first-page":"e003148","DOI":"10.1161\/CIRCINTERVENTIONS.115.003148","volume":"9","author":"E Moscarella","year":"2016","unstructured":"Moscarella, E. et al. Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: a multicenter italian experience. Circ. Cardiovasc. Interv. 9, e003148 (2016).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR64","doi-asserted-by":"crossref","first-page":"627","DOI":"10.5603\/KP.a2015.0250","volume":"74","author":"RJ Gil","year":"2016","unstructured":"Gil, R. J. et al. The use of bioresorbable vascular scaffold Absorb BVS\u00ae in patients with stable coronary artery disease: one-year results with special focus on the hybrid BVS and DES treatment. Kardiol Pol. 74, 627\u2013633 (2016).","journal-title":"Kardiol Pol."},{"key":"BFnrcardio2016151_CR65","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0735-1097(16)30233-9","volume":"67","author":"J de Ribamar Costa","year":"2016","unstructured":"de Ribamar Costa, J. et al. Initial results of the FANTOM 1 trial: a first-in-man evaluation of a novel, radiopaque sirolimus-eluting bioresorbable vascular scaffold. J. Am. Coll. Cardiol. 67, 232\u2013232 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016151_CR66","unstructured":"Abizaid, A. Reva Fantom: differentiating features and studies. Presented at: Joint Interventional Meeting, 11\u201313 Feb 2016, Milan, Italy."},{"key":"BFnrcardio2016151_CR67","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/S0140-6736(07)60853-8","volume":"369","author":"R Erbel","year":"2007","unstructured":"Erbel, R. et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369, 1869\u20131875 (2007).","journal-title":"Lancet"},{"key":"BFnrcardio2016151_CR68","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S0140-6736(12)61765-6","volume":"381","author":"M Haude","year":"2013","unstructured":"Haude, M. et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 381, 836\u2013844 (2013).","journal-title":"Lancet"},{"key":"BFnrcardio2016151_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5339\/gcsp.2015.63","volume":"2015","author":"YH Bouchi","year":"2015","unstructured":"Bouchi, Y. H. & Gogas, B. D. Biocorrodible metals for coronary revascularization: lessons from PROGRESS-AMS, BIOSOLVE-I, and BIOSOLVE-II. Glob. Cardiol. Sci. Pract. 2015, 63 (2015).","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"BFnrcardio2016151_CR70","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1161\/CIRCULATIONAHA.112.103911","volume":"125","author":"R Waksman","year":"2012","unstructured":"Waksman, R. The disappearing stent: when plastic replaces metal. Circulation 125, 2291\u20132294 (2012).","journal-title":"Circulation"},{"key":"BFnrcardio2016151_CR71","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1161\/01.CIR.92.5.1230","volume":"92","author":"C Indolfi","year":"1995","unstructured":"Indolfi, C. et al. Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation 92, 1230\u20131235 (1995).","journal-title":"Circulation"},{"key":"BFnrcardio2016151_CR72","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12265-014-9571-7","volume":"7","author":"MJ Lipinski","year":"2014","unstructured":"Lipinski, M. J., Escarcega, R. O., Lhermusier, T. & Waksman, R. The effects of novel, bioresorbable scaffolds on coronary vascular pathophysiology. J. Cardiovasc. Transl Res. 7, 413\u2013425 (2014).","journal-title":"J. Cardiovasc. Transl Res."},{"key":"BFnrcardio2016151_CR73","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1161\/CIRCULATIONAHA.109.921528","volume":"122","author":"Y Onuma","year":"2010","unstructured":"Onuma, Y. et al. Intra-coronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122, 2288\u20132300 (2010).","journal-title":"Circulation"},{"key":"BFnrcardio2016151_CR74","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jcin.2015.09.024","volume":"9","author":"MJ Lipinski","year":"2016","unstructured":"Lipinski, M. J. et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold a systematic review and meta-analysis. JACC Cardiovasc. Interv. 9, 12\u201324 (2016).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR75","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MCA.0000000000000318","volume":"27","author":"G \u00c7i\u00e7ek","year":"2016","unstructured":"\u00c7i\u00e7ek, G., A\u00e7\u0131kgoz, S. K., Yayla, \u00c7., Kundi, H. & \u00cdleri, M. Magnesium as a predictor of acute stent thrombosis in patients with ST-segment elevation myocardial infarction who underwent primary angioplasty. Coron. Artery Dis. 27, 47\u201351 (2016).","journal-title":"Coron. Artery Dis."},{"key":"BFnrcardio2016151_CR76","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4244\/EIJY15M10_07","volume":"12","author":"ML Fokkema","year":"2016","unstructured":"Fokkema, M. L. et al. Outcome after percutaneous coronary intervention for different indications: long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). EuroIntervention 12, 303\u2013311 (2016).","journal-title":"EuroIntervention"},{"key":"BFnrcardio2016151_CR77","unstructured":"Petronio, A. S. 30-day results of the Italian diffuse\/multivessel disease ABSORB prospective registry (IT-DISAPPEARS). Presented at: EuroPCR 2016, 17 May 2016, Paris, France."},{"key":"BFnrcardio2016151_CR78","unstructured":"Cortese, B. 30-day outcome of the Italian ABSORB registry (RAI), a prospective registry of consecutive patients treated with biovascular scaffold. Presented at: EuroPCR 2016, 17 May 2016, Paris, France."},{"key":"BFnrcardio2016151_CR79","unstructured":"Koning, R. France ABSORB registry: in-hospital and one-month results in 2,000 patients. Presented at: EuroPCR 2016, 17 May 2016, Paris, France."},{"key":"BFnrcardio2016151_CR80","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jacc.2015.11.060","volume":"67","author":"PW Serruys","year":"2016","unstructured":"Serruys, P. W. et al. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J. Am. Coll. Cardiol. 67, 766\u2013776 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio2016151_CR81","doi-asserted-by":"crossref","unstructured":"Yahagi, K., Virmani, R. & Kesavamoorthy, B. Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy. Cardiovasc. Interv Ther. 31 Oct 2015 [epub ahead of print].","DOI":"10.1007\/s12928-015-0364-y"},{"key":"BFnrcardio2016151_CR82","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/eurheartj\/ehu026","volume":"35","author":"S Silber","year":"2014","unstructured":"Silber, S. et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur. Heart J. 35, 1949\u20131956 (2014).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio2016151_CR83","unstructured":"Van Geuns, R. J. Effect of DAPT termination at 12 months on very late scaffold thrombosis in regular clinical practice: data on a regional collaboration including 868 patients. Presented at: EuroPCR 2016, 17 May 2016, Paris, France."},{"key":"BFnrcardio2016151_CR84","doi-asserted-by":"publisher","first-page":"3968206","DOI":"10.1155\/2016\/3968206","volume":"2016","author":"A Carino","year":"2016","unstructured":"Carino, A. et al. Modulation of circulating microRNAs levels during the switch from clopidogrel to ticagrelor. Biomed. Res. Int. 2016, 3968206 (2016).","journal-title":"Biomed. Res. Int."},{"key":"BFnrcardio2016151_CR85","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1161\/CIRCINTERVENTIONS.113.000512","volume":"7","author":"G Caiazzo","year":"2014","unstructured":"Caiazzo, G. et al. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. Circ. Cardiovasc. Interv. 7, 104\u2013112 (2014).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"BFnrcardio2016151_CR86","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","volume":"12","author":"F Franchi","year":"2015","unstructured":"Franchi, F. & Angiolillo, D. J. Novel antiplatelet agents in acute coronary syndrome. Nat. Rev. Cardiol. 12, 30\u201347 (2015).","journal-title":"Nat. Rev. Cardiol."},{"key":"BFnrcardio2016151_CR87","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1253\/circj.CJ-15-1325","volume":"80","author":"H Tateishi","year":"2016","unstructured":"Tateishi, H. et al. Edge vascular response after resorption of the everolimus-eluting bioresorbable vascular scaffold \u2014 a 5-year serial optical coherence tomography study. Circ. J. 80, 1131\u20131141 (2016).","journal-title":"Circ. J."},{"key":"BFnrcardio2016151_CR88","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12872-016-0296-1","volume":"16","author":"D Dalos","year":"2016","unstructured":"Dalos, D. et al. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent. BMC Cardiovasc. Disord. 16, 104 (2016).","journal-title":"BMC Cardiovasc. Disord."},{"key":"BFnrcardio2016151_CR89","doi-asserted-by":"publisher","first-page":"e002375","DOI":"10.1161\/CIRCINTERVENTIONS.115.002375","volume":"8","author":"S De Rosa","year":"2015","unstructured":"De Rosa, S. & Indolfi, C. Letter by De Rosa and Indolfi regarding article, \u201cClinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations\u201d. Circ. Cardiovasc. Interv. 8, e002375 (2015).","journal-title":"Circ. Cardiovasc. Interv."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.151","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2016.151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T21:53:50Z","timestamp":1749592430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2016.151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,29]]},"references-count":89,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFnrcardio2016151"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2016.151","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,29]]},"assertion":[{"value":"29 September 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.I. has received educational grants from Abbott Vascular. S.D.R. and A.C. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}